ArticleJournal of cancer survivorship : research and practice2018
Impact of chemotherapy-induced neurotoxicities on adult cancer survivors' symptom burden and quality of life.
Article in Journal of cancer survivorship : research and practice, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 46 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Auricular Point Acupressure to Manage Chemotherapy Induced Neuropathy
Wearable Focal Vibration for Chemotherapy-Induced Peripheral Neuropathy
Who cites it
46 citing papers in PubMed, 3 syntheses or guidelines pooled it, 76 citations in OpenAlex.
- Ototoxicity prognostic models in adult and pediatric cancer patients: a rapid review.Journal of cancer survivorship : research and practice · 2023Pooled it
- Treatment for chemotherapy-induced peripheral neuropathy: A systematic review of randomized control trials.Frontiers in pharmacology · 2022Pooled it
- Bibliometric Analysis Reveals a 20-Year Research Trend for Chemotherapy-Induced Peripheral Neuropathy.Frontiers in neurology · 2021Pooled it
- A case-control study investigating the impact of gradient pressure therapy on chemotherapy-induced peripheral neuropathy symptoms and daily activities in paclitaxel-treated patients.Journal of the Egyptian National Cancer Institute · 2025Trial
- Examining the effectiveness of combination therapy in alleviating peripheral neuropathy and sleep disorders in breast cancer patients receiving chemotherapy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Trial
- Therapeutic effects of compression therapy on taxane-induced peripheral neuropathy incidence, negative emotions, and sleep disorders in patients with breast cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Trial
- A Randomized Sham-Controlled Mixed Methods Pilot Study of the Feasibility of Acupuncture for Chemotherapy-Induced Neuropathy: Lessons Learned From Patient Experiences in Integrative Cancer Care.Integrative cancer therapiesTrial
- Ototoxicity beyond platinum-based derivatives.Cancer chemotherapy and pharmacology · 2026Article
- A machine learning approach to profiling anxiety risk among cancer patients on treatment.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Hearing/vestibular problems, racial differences, and associations with physical function impairment among breast cancer survivors.JNCI cancer spectrum · 2026Article
- Serum neurofilament light chain (sNFL) as a predictive biomarker for Chemotherapy-induced peripheral neurotoxicity (CIPN): consideration of current evidence, validation steps, and barriers to CIPN biomarker implementation in clinical practice-a narrative review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Review
- Cancer therapy-induced ototoxicity: Current challenges and emerging management strategies.Animal models and experimental medicine · 2026Review
- Early Identification of Mild Cognitive Impairment in Person with Cancer Undergoing Chemotherapy: Associations with Anxiety, Sleep Disturbance and Depression.Healthcare (Basel, Switzerland) · 2025Review
- Survivors' perspectives on cisplatin-induced ototoxicity and barriers to ototoxicity monitoring.Journal of cancer survivorship : research and practice · 2025Article
- A novel isoquinoline mitophagy inducer ameliorates paclitaxel-induced peripheral neuropathy in Drosophila and mouse models.Scientific reports · 2025Article
- Clavulanic acid prevents paclitaxel-induced neuropathic pain through a systemic and central anti-inflammatory effect in mice.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025Article
- Sex differences in PD-L1-induced analgesia in paclitaxel-induced peripheral neuropathy mice depend on TRPV1-based inhibition of CGRP.CNS neuroscience & therapeutics · 2024Article
- Effect of gradient pressure therapy on the prevention of chemotherapy-induced peripheral neuropathy in patients with breast cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- Quality of Life and Associated Factors among Cancer Patients Receiving Chemotherapy during the COVID-19 Pandemic in Thailand.International journal of environmental research and public health · 2024Article
- [The transformative effect of artificial intelligence in hospitals : The focus is on the individual].Innere Medizin (Heidelberg, Germany) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
Abstract
purposeLimited information is available on the impact of chemotherapy (CTX)-induced neurotoxicity on adult survivors' symptom experience and quality of life (QOL). Purposes were to describe occurrence of hearing loss and tinnitus and evaluate for differences in phenotypic characteristics and measures of sensation, balance, perceived stress, symptom burden, and QOL between survivors who received neurotoxic CTX and did (i.e., neurotoxicity group) and did not (i.e., no neurotoxicity group) develop neurotoxicity. Neurotoxicity was defined as the presence of chemotherapy-induced neuropathy (CIN), hearing loss, and tinnitus. Survivors in the no neurotoxicity group had none of these conditions.
methodsSurvivors (n = 609) completed questionnaires that evaluated hearing loss, tinnitus, stress, symptoms, and QOL. Objective measures of sensation and balance were evaluated.
resultsOf the 609 survivors evaluated, 68.6% did and 31.4% did not have CIN. Of the survivors without CIN, 42.4% reported either hearing loss and/or tinnitus and 48.1% of the survivors with CIN reported some form of ototoxicity. Compared to the no neurotoxicity group (n = 110), survivors in the neurotoxicity group (n = 85) were older, were less likely to be employed, had a higher comorbidity burden, and a higher symptom burden, higher levels of perceived stress, and poorer QOL (all p < .05).
conclusionsFindings suggest that CIN, hearing loss, and tinnitus are relatively common conditions in survivors who received neurotoxic CTX. IMPLICATIONS FOR CANCER SURVIVORS: Survivors need to be evaluated for these neurotoxicities and receive appropriate interventions. Referrals to audiologists and physical therapists are warranted to improve survivors' hearing ability, functional status, and QOL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.